Zhaorong Li

Broad Institute — United States

Neuroscience · Life Sciences

23h-index3.0kcitations77works5.62yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroinflammation and Neurodegeneration Mechanisms(11), Single-cell and spatial transcriptomics(9), interferon and immune responses(8), Genomics and Chromatin Dynamics(7), Immune Cell Function and Interaction(7)

Publications77 total

Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy

3 cited

Nature Cancer·2025· 3 cited

Viral transcriptional regulators extensively rewire host pathways through diverse mechanisms

2025Open Access

Neuronal activity promotes repair by microglial reprogramming following demyelination

2025

Table S2 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy

2025Open Access

Table S1 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy

2025Open Access

Figure S8 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy

2025Open Access

Figure S7 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy

2025Open Access

Figure S6 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy

2025Open Access

Figure S10 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy

2025Open Access

Figure S4 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy

2025Open Access

Figure S3 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy

2025Open Access

Figure S11 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy

2025Open Access

Figure S1 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy

2025Open Access

Figure S9 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy

2025Open Access

Figure S5 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy

2025Open Access

Figure S2 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy

2025Open Access

Data from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy

2025Open Access

Author Correction: Disease-associated astrocyte epigenetic memory promotes CNS pathology

Nature·2025Open Access

Loss of NOTCH2 creates a TRIM28-dependent vulnerability in small cell lung cancer

Developmental Cell·2025

Eradicating Drug-tolerant Persister Cells in EGFR- Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy

6 cited

Cancer Discovery·2025· 6 citedOpen Access

page 1 of 4Next →

Frequent Co-authors

Francisco J. Quintana(28), Michael A. Wheeler(18), Federico Giovannoni(17), Liliana M. Sanmarco(16), Hong‐Gyun Lee(14), Camilo Faust Akl(13), Veit Rothhammer(12), Joseph M. Rone(11), Iain C. Clark(10), Alexandre Prat(10), Carolina Manganeli Polonio(10), Jessica E. Kenison(10), Gavin Piester(10), Stéphanie Zandee(9), Cristina Gutiérrez‐Vázquez(9), Chun‐Cheih Chao(9), Tomer Illouz(9), Jack P. Antel(8), Joon-Hyuk Lee(8), Emily Tjon(7)